<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="16">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    https://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 08, 2015</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01881230</url>
  </required_header>
  <id_info>
    <org_study_id>ABI-007-MBC-001</org_study_id>
    <secondary_id>2013-000113-20</secondary_id>
    <nct_id>NCT01881230</nct_id>
  </id_info>
  <brief_title>Evaluate Risk/Benefit of Nab Paclitaxel in Combination With Gemcitabine and Carboplatin Compared to Gemcitabine and Carboplatin in Triple Negative Metastatic Breast Cancer (or Metastatic Triple Negative Breast Cancer)</brief_title>
  <acronym>tnAcity</acronym>
  <official_title>A Phase 2/3, Multi-Center, Open-Label, Randomized Study of Weekly Nab®-Paclitaxel in Combination With Gemcitabine or Carboplatin, Compared to Gemcitabine/Carboplatin, as First Line Treatment in Subjects With ER, PgR, and HER2 Negative (Triple Negative) Metastatic Breast Cancer</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Celgene Corporation</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Celgene Corporation</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <authority>Australia: Department of Health and Ageing Therapeutic Goods Administration</authority>
    <authority>Austria: Agency for Health and Food Safety</authority>
    <authority>Brazil: Ministry of Health</authority>
    <authority>Canada: Health Canada</authority>
    <authority>France: Agence Nationale de Sécurité du Médicament et des produits de santé</authority>
    <authority>Germany: Federal Institute for Drugs and Medical Devices</authority>
    <authority>Greece: National Organization of Medicines</authority>
    <authority>Italy: The Italian Medicines Agency</authority>
    <authority>Portugal: National Pharmacy and Medicines Institute</authority>
    <authority>Spain: Spanish Agency of Medicines</authority>
    <authority>United Kingdom: Medicines and Healthcare Products Regulatory Agency</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare the safety and efficacy of nab-paclitaxel in
      combination with either gemcitabine or carboplatin to the combination of gemcitabine and
      carboplatin as first line treatment in female subjects with triple negative metastatic
      breast cancer (TNMBC) or metastatic triple negative breast cancer.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      ABI-007-MBC- 001 is a Phase 2/3, multicenter, open-label, randomized, study that will
      compare the safety and efficacy of weekly nab-paclitaxel in combination with gemcitabine or
      carboplatin to the combination of gemcitabine and carboplatin as first line therapy in
      female subjects with Estrogen Receptor (ER), Progesterone Receptor (PgR), and human
      epidermal growth factor receptor 2  (HER2) negative (triple negative) metastatic breast
      cancer (TNMBC) or metastatic triple negative breast cancer. In the phase 2 portion of the
      study, the combinations of nab-paclitaxel plus gemcitabine and nab-paclitaxel plus
      carboplatin will be evaluated, and a comparator arm of gemcitabine combined with carboplatin
      will be used. In the phase 3 portion of the study, the selected nab-paclitaxel combination
      treatment will be compared to gemcitabine combined with carboplatin to evaluate progression
      free survival, safety and tolerability, overall survival, disease control rate and duration
      of response in women with metastatic triple negative breast cancer.
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>September 2013</start_date>
  <completion_date type="Anticipated">December 2016</completion_date>
  <primary_completion_date type="Anticipated">October 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the randomization date to the start of disease progression or subject death from any cause (progression assessed by investigator using Response Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1 guidelines) for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Progression Free Survival (PFS) for triple negative metastatic breast cancer subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time from the randomization date to the start of disease progression or subject death from any cause (assessment based on an independent blinded radiologist(s) evaluation using RECIST 1.1 guidelines  for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Investigator-determined Overall Response Rate (ORR) (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR) or partial response (PR) based on investigator assessment of response using RECIST 1.1 guidelines</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who initiated Cycle 6 receiving doublet combination therapy (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the Percentage of subjects who initiated Cycle 6 of treatment</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator determined Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 2)</measure>
    <time_frame>Up to approximately 18 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Defined as the time between randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety for triple negative metastatic breast cancer (TNMBC) subjects (Phase 2)</measure>
    <time_frame>up to approximately 19 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Incidence/Grade of Treatment Emergent Adverse Events (TEAEs), Serious Adverse Events (SAEs), laboratory abnormalities Percentage and number of subjects who discontinued for adverse event</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Independent blinded radiologists-determined Overall Response Rate (ORR) (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete or partial response according to RECIST 1.1 guidelines determined by independent, blinded radiologist(s)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall Survival (OS) for triple negative metastatic breast cancer (TNMBC) subjects  (Phase 3)</measure>
    <time_frame>Up to approximately 66 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Time between randomization and death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compare disease control rate for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Complete response (CR), Partial response (PR), and Stable Disease (SD) more than or equal to 16 weeks for triple negative metastatic breast cancer (TNMBC) subjects</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of Response for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)</measure>
    <time_frame>Up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>Period from objective complete or partial response (whichever is first recorded) until the first date that progression free survival event is documented</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Safety of each treatment regimen for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)</measure>
    <time_frame>Up to approximately 47 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>Assessment based on Adverse Events (AEs) , Serious Adverse Events (SAEs), laboratory abnormalities in triple negative metastatic breast cancer (TNMBC) subjects .</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Investigator assessed Progression Free Survival (PFS)for triple negative metastatic breast cancer (TNMBC) subjects (Phase 3)</measure>
    <time_frame>up to approximately 46 months</time_frame>
    <safety_issue>No</safety_issue>
    <description>PFS is defined as the number of subjects who survive without progressing</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Incidence of subjects experiencing dose modifications (dose interruptions and reductions);</measure>
    <time_frame>Up to 19 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>The number of subjects with dose interruptions and reductions experienced by participants that occurred during the treatment period.  Dose interruptions and reductions are typically caused by clinically significant laboratory abnormalities and /or treatment emergent adverse events/toxicities.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percentage of subjects who discontinued from all study treatment adverse event</measure>
    <time_frame>Up to 19 months</time_frame>
    <safety_issue>Yes</safety_issue>
    <description>An adverse event (AE) is any noxious, unintended, or untoward medical occurrence that may appear or worsen in a subject during the course of a study. It may be a new intercurrent illness, a worsening concomitant illness, an injury, or any concomitant impairment of the subject's health, including laboratory test values (as specified by the criteria below), regardless of etiology. Any worsening (ie, any clinically significant adverse change in the frequency or intensity of a preexisting condition) should be considered an AE</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">185</enrollment>
  <condition>Breast Tumor</condition>
  <condition>Breast Cancer</condition>
  <condition>Cancer of the Breast</condition>
  <condition>Estrogen Receptor- Negative Breast Cancer</condition>
  <condition>HER2- Negative Breast Cancer</condition>
  <condition>Progesterone Receptor- Negative Breast Cancer</condition>
  <condition>Recurrent Breast Cancer</condition>
  <condition>Stage IV Breast Cancer</condition>
  <condition>Triple-negative Breast Cancer</condition>
  <condition>Triple-negative Metastatic Breast Cancer</condition>
  <condition>Metastatic Breast Cancer</condition>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 125mg/m^2 plus gemcitabine 1000mg/m^2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Phase 2) Treatment Arm A: nab-Paclitaxel 125mg/m^2 on Days 1 and 8 by intravenousI (IV) administration over 30 minutes, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration over 30 minutes in triple negative metastatic breast cancer (TNMBC) subjects</description>
  </arm_group>
  <arm_group>
    <arm_group_label>nab-Paclitaxel 125mg/m^2 plus carboplatin AUC2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>(Phase 2) Treatment Arm B: nab-Paclitaxel 125 mg/m^2 on Days 1 and 8 by IV administration without hypersensitivity prophylaxis, followed by carboplatin AUC 2 on Days 1 and 8 by IV administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Phase 2) Treatment Arm C: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration followed by carboplatin AUC2 on Days 1 and 8 by IV administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Phase 3 Treatment Arm 1 -Selected Phase 2 nab paclitaxel treatment arm of either nab-Paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration without hypersensitivity prophylaxis, followed by gemcitabine 1000 mg/m2 on Days 1 and 8 by IV administration OR  nab-Paclitaxel 125 mg/m2 on Days 1 and 8 by IV administration without hypersensitivity prophylaxis, followed by carboplatin AUC 2 on Days 1 and 8 by IV administration</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC 2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>(Phase 3) Treatment Arm 2: Gemcitabine 1000 mg/m^2 on Days 1 and 8 by IV administration over 30 minutes, followed by carboplatin AUC2 on Days 1 and 8 by IV administration</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>nab-Paclitaxel 125 mg/m2 plus carboplatin AUC 2 in triple negative metastatic breast cancer (TNMBC) subjects</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m^2 plus carboplatin AUC2</arm_group_label>
    <other_name>Abraxane</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Carboplatin AUC 2</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m^2 plus carboplatin AUC2</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC2</arm_group_label>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC 2</arm_group_label>
    <other_name>Paraplatin,</other_name>
    <other_name>Paraplatin AQ</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine 1000 mg</intervention_name>
    <arm_group_label>nab-Paclitaxel 125mg/m^2 plus gemcitabine 1000mg/m^2</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC2</arm_group_label>
    <arm_group_label>Selected nab Paclitaxel arm from Phase 2 inTNMBC subjects</arm_group_label>
    <arm_group_label>Gemcitabine 1000mg/m^2 plus carboplatin AUC 2</arm_group_label>
    <other_name>Gemzar</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:   A subject will be eligible for inclusion in this study only if all
        of the following criteria are met:

          1. Female subjects, age ≥ 18 years  at the time informed consent is signed

          2. Pathologically confirmed adenocarcinoma of the breast

          3. Pathologically confirmed as triple negative, source documented, defined as both of
             the following

               1. Estrogen Receptor (ER) and Progesterone Receptor (PgR) negative: &lt; 1% of tumor
                  cell nuclei are immunoreactive in the presence of evidence that the sample can
                  express ER or PgR (positive intrinsic controls)

               2. Human Epidermal Growth Factor Receptor 2 (HER2) negative as per American Society
                  of Clinical Oncology - College of American Pathologists (ASCO/CAP) guidelines i.
                  Immunohistochemistry (IHC) 0 or 1 Fluorescence In Situ Hybridization (FISH)
                  negative (or equivalent negative test).  Subjects with IHC 2 must have a
                  negative by Fluorescence In Situ Hybridization (FISH),, (or equivalent negative
                  test).

          4. Subjects with prior breast cancer history of different phenotypes (ie, ER/PgR/HER2
             positive) must have pathologic confirmation of triple negative disease in at least
             one of the current sites of metastasis

          5. Subjects must have received prior adjuvant or neoadjuvant anthracycline therapy;
             unless (a) anthracycline treatment was not indicated or was not the best treatment
             option for the subject in the opinion of the treating physician; and (b)
             anthracycline treatment remains not indicated or, in the opinion of the treating
             physician, is not the best treatment option for the subject's metastatic disease.

             a.  Newly diagnosed subjects presenting with TNMBC are eligible for the study if
             anthracycline treatment is not indicated or is not the best treatment option for the
             subject in the opinion of the treating physician.

          6. Subjects with measurable metastatic disease, defined by Response Evaluation Criteria
             in Solid Tumors 1.1 (RECIST 1.1) guidelines

          7. Life expectancy ≥ 16 weeks from randomization

          8. No prior cytotoxic chemotherapy for metastatic breast cancer. Prior immunotherapy
             and/or monoclonal antibody therapy are acceptable. Prior treatments must have been
             discontinued at least 30 days prior to start of study treatment and all related
             toxicities must have resolved to Grade 1 or less.

          9. Prior neoadjuvant or adjuvant chemotherapy, if given, must have been completed at
             least 6 months before randomization with all related toxicities resolved, and
             documented evidence of disease progression per RECIST 1.1 guidelines is required.

             a.  If prior neoadjuvant or adjuvant chemotherapy contained taxane, gemcitabine, or
             platinum agents, the treatment must have completed at least 12 months before
             randomization

         10. Prior radiotherapy must have completed before randomization, with full recovery from
             acute radiation side effects.  At least one measurable lesion must be completely
             outside the radiation portal or there must be unequivocal radiologic or clinical exam
             proof of progressive disease within the radiation portal, in accordance with RECIST
             1.1 guidelines

         11. At least 30 days from major surgery before  randomization, with full recovery

         12. Eastern Cooperative Oncology Group (ECOG) performance status 0-1

         13. Subject has the following blood counts at screening:

               -  Absolute Neutrophil Count (ANC) ≥ 1500/mm^2 ;

               -  Platelets ≥ 100,000/mm^2 ;

               -  Hemoglobin (Hgb) ≥ 9 g/dL

         14. Subject has the following blood chemistry levels at screening:

               -  Aspartate aminotransferase (AST) Serum glutamic-oxaloacetic transaminase (SGOT),
                  Alanine Aminotransferase (ALT ) Serum Glutamic Pyruvate Transaminase (SGPT) ≤
                  2.5 x upper limit of normal range (ULN); if hepatic metastases present ≤ 5.0 x
                  ULN

               -  Total serum bilirubin ≤ ULN; or total bilirubin ≤ 3.0 × ULN with direct
                  bilirubin within normal range in  subjects with documented Gilbert's Syndrome

               -  Creatinine clearance &gt; 60 mL/min (by Cockcroft-Gault)

         15. Females of child-bearing potential [defined as a sexually mature women who (1) have
             not undergone hysterectomy (the surgical removal of the uterus) or bilateral
             oophorectomy (the surgical removal of both ovaries) or (2) have not been naturally
             postmenopausal for at least 24 consecutive months (i.e., has had menses at any time
             during the preceding 24 consecutive months)] must:

               -  Demonstrate a negative serum pregnancy test result at screening (performed by
                  central lab) confirmed by local negative urine pregnancy dipstick within 72
                  hours prior to the first dose of IP); pregnancy test with sensitivity of at
                  least 25 mIU/mL; and

               -  Either commit to true abstinence* from heterosexual contact (which must be
                  reviewed on a monthly basis) or agree to use, and be able to comply with, two
                  physician approved effective contraception methods (oral, injectable, or
                  implantable hormonal contraceptive; tubal ligation; intra-uterine device;
                  barrier contraceptive with spermicide; or vasectomized partner) without
                  interruption for 28 days or longer as required by local guidelines, prior to
                  starting study drug, during the study therapy (including dose interruptions),
                  and for 28 days after discontinuation of the study or longer as required by
                  local guidelines

         16. Females must abstain from breastfeeding starting at randomization, during study
             participation and for 28 days or longer as required by local guidelines, after IP
             discontinuation

         17. Understand and voluntarily sign an informed consent document prior to any study
             related assessments/procedures are conducted

         18. Able to adhere to the study visit schedule and other protocol requirements

        Exclusion Criteria:

        A subject will not be eligible for inclusion in this study if any of the following
        criteria apply:

          1. Male subjects

          2. Concurrent chemotherapy or any other anti tumor therapy for breast cancer. Prior
             immunotherapy &amp; monoclonal antibody therapy are acceptable.

          3. Subjects who received prior cytotoxic chemotherapy after incomplete resection of
             locoregional recurrent disease

          4. History of, or known current evidence of brain metastasis, including leptomeningeal
             involvement.

          5. Subjects with bone as the only site of metastatic disease

          6. Subjects with regional lymph node  as the only site of metastatic disease

          7. Serious intercurrent medical or psychiatric illness, including serious active
             infection

          8. History of class II-IV congestive heart failure or myocardial infarction within 6
             months of randomization

          9. History of other primary malignancy in the last 5 years prior to randomization.
             Subjects with prior breast cancer history are eligible,  however, the most recently
             obtained biopsy must demonstrate triple negative disease (source documented).
             Subjects with prior history of in situ cancer or basal or localized squamous cell
             skin cancer are eligible.

         10. Subjects with a history of interstitial lung disease, history of slowly progressive
             dyspnea and unproductive cough, sarcoidosis, silicosis, idiopathic pulmonary
             fibrosis, pulmonary hypersensitivity pneumonitis or multiple uncontrolled or unstable
             allergies which, in the opinion of the investigator, may lead to serious
             complications

         11. Peripheral neuropathy Grade ≥ 2 by National Cancer Institute Common Terminology
             Criteria for Adverse Events (NCI CTCAE) v4.0

         12. Subjects who have received an investigational product within the previous 4 weeks
             prior to randomization

         13. Subject is currently enrolled, or will enroll in a different clinical study in which
             investigational therapeutic procedures are performed or investigational therapies are
             administered while participating in this study

         14. Pregnant or nursing women

         15. Subjects with prior hypersensitivity to nab-paclitaxel, gemcitabine, carboplatin or
             any other platin, or nucleoside analogue agents

         16. Any significant medical condition, laboratory abnormality, or psychiatric illness
             that would prevent the subject from participating in the study

         17. Any condition including the presence of laboratory abnormalities, which places the
             subject at unacceptable risk if she were to participate in the study

         18. Any condition that confounds the ability to interpret data from the study

         19. History of seropositive human immunodeficiency virus (HIV)

         20. Subjects who are receiving immunosuppressive or myelosuppressive medications that
             would, in the opinion of the investigator, increase the risk of serious neutropenic
             complications
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Debora Barton, M.D.</last_name>
    <role>Study Director</role>
    <affiliation>Celgene Corporation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Ironwood Cancer and Research Center</name>
      <address>
        <city>Chandler</city>
        <state>Arizona</state>
        <zip>85224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Center for Cancer Care</name>
      <address>
        <city>Glendale</city>
        <state>Arizona</state>
        <zip>85306</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arizona Cancer Research Alliance</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85251</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic Arizona</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Highlands Oncology Group</name>
      <address>
        <city>Fayetteville</city>
        <state>Arkansas</state>
        <zip>72703</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Pacific Cancer Medical Center Inc</name>
      <address>
        <city>Anaheim</city>
        <state>California</state>
        <zip>92801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>California Cancer Associates for Research and Excellence (cCARE)</name>
      <address>
        <city>Escondido</city>
        <state>California</state>
        <zip>92025</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UC San Diego Moores Cancer Center</name>
      <address>
        <city>La Jolla</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wilshire Oncology Medical Group, Inc</name>
      <address>
        <city>La Verne</city>
        <state>California</state>
        <zip>91750</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Translational Research Management</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Coastal Integrative Cancer Care</name>
      <address>
        <city>San Luis Obispo</city>
        <state>California</state>
        <zip>93401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Central Coast Medical Oncology Corporation</name>
      <address>
        <city>Santa Maria</city>
        <state>California</state>
        <zip>93454</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Redwood Regional Medical Group, INC</name>
      <address>
        <city>Santa Rosa</city>
        <state>California</state>
        <zip>95403</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Hematology-Oncology</name>
      <address>
        <city>Boca Raton</city>
        <state>Florida</state>
        <zip>33486</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Memorial Breast Cancer Center</name>
      <address>
        <city>Hollywood</city>
        <state>Florida</state>
        <zip>33021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic - Jacksonville</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Miami School of Medicine</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>Sarasota</city>
        <state>Florida</state>
        <zip>34232</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>St. Petersburg</city>
        <state>Florida</state>
        <zip>33705</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Florida Cancer Specialists</name>
      <address>
        <city>West Palm Beach</city>
        <state>Florida</state>
        <zip>33401</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Joliet Oncology-Hematology Associates, Ltd</name>
      <address>
        <city>Joliet</city>
        <state>Illinois</state>
        <zip>60435</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Carle Cancer Center</name>
      <address>
        <city>Urbana</city>
        <state>Illinois</state>
        <zip>61801</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Investigative Clinical Research of Indiana, LLC</name>
      <address>
        <city>Indianapolis</city>
        <state>Indiana</state>
        <zip>46254</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of South Alabama Mitchell Cancer Institute</name>
      <address>
        <city>Lafayette</city>
        <state>Louisiana</state>
        <zip>70503</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Maryland School of Med</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Cancer and Blood Disorders, PC</name>
      <address>
        <city>Bethesda</city>
        <state>Maryland</state>
        <zip>20817</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202-268</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Oncology Hematology, PA</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55407</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Midwest Physicians Group</name>
      <address>
        <city>Kansas City</city>
        <state>Missouri</state>
        <zip>64132</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Missouri Baptist Medical Center</name>
      <address>
        <city>St. Louis</city>
        <state>Missouri</state>
        <zip>63131</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>New Hampshire Oncology Hematology</name>
      <address>
        <city>Hooksett</city>
        <state>New Hampshire</state>
        <zip>03106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dartmouth Hitchcock Medical Center Norris Cotton Cancer Center</name>
      <address>
        <city>Lebanon</city>
        <state>New Hampshire</state>
        <zip>03756</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Englewood Hospital and Medical Center</name>
      <address>
        <city>Englewood</city>
        <state>New Jersey</state>
        <zip>07631</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of CNY</name>
      <address>
        <city>East Syracuse</city>
        <state>New York</state>
        <zip>13057</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>NYU Langone Arena Oncology</name>
      <address>
        <city>Lake Success</city>
        <state>New York</state>
        <zip>11042</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinical Research Alliance</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10021</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alamance Regional Medical Cancer Center</name>
      <address>
        <city>Burlington</city>
        <state>North Carolina</state>
        <zip>27215-8700</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Oncology Hematology Care</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45242</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Cincinnatti</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Mark H Zangmeister Center</name>
      <address>
        <city>Columbus</city>
        <state>Ohio</state>
        <zip>43219</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Toledo Community Oncology Program</name>
      <address>
        <city>Toledo</city>
        <state>Ohio</state>
        <zip>43623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Centers of Southwest Oklahoma</name>
      <address>
        <city>Lawton</city>
        <state>Oklahoma</state>
        <zip>73505</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>North Bend Medical Center</name>
      <address>
        <city>Coos Bay</city>
        <state>Oregon</state>
        <zip>97420</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Northwest Cancer Specialists, P.C. - Hoyt</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Providence Portland Medical Center</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>St Mary Medical Center</name>
      <address>
        <city>Langhorne</city>
        <state>Pennsylvania</state>
        <zip>19047</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Magee Women's Hospital</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Carolina Oncology Associates</name>
      <address>
        <city>Columbia</city>
        <state>South Carolina</state>
        <zip>29210</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chattanooga Oncology Hematology Associates</name>
      <address>
        <city>Chattanooga</city>
        <state>Tennessee</state>
        <zip>37404</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology, PA- Dallas</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75246</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Center for Cancer and Blood Disorders</name>
      <address>
        <city>Fort Worth</city>
        <state>Texas</state>
        <zip>76104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>UT Physicians General Medicine</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Cancer Care Centers of South Texas - Loop</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Texas Oncology P.A.- Tyler</name>
      <address>
        <city>Tyler</city>
        <state>Texas</state>
        <zip>75702</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hematology Oncology Associates of Fredericksburg</name>
      <address>
        <city>Fredericksburg</city>
        <state>Virginia</state>
        <zip>22408</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Delta Hematologyoncology Associates</name>
      <address>
        <city>Portsmouth</city>
        <state>Virginia</state>
        <zip>23704</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Virginia Cancer Institute</name>
      <address>
        <city>Richmond</city>
        <state>Virginia</state>
        <zip>23230</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medical Oncology Associates</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99208</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Edwards Comprehensive Cancer Center</name>
      <address>
        <city>Huntington</city>
        <state>West Virginia</state>
        <zip>25701</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Saint Vincent Hospital</name>
      <address>
        <city>Green Bay</city>
        <state>Wisconsin</state>
        <zip>54301</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Columbia St Marys Cancer Center</name>
      <address>
        <city>Milwaukee</city>
        <state>Wisconsin</state>
        <zip>53211</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Canberra Hospital</name>
      <address>
        <city>Garran</city>
        <state>Australian Capital Territory</state>
        <zip>2605</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frankston Hospital Oncology Research</name>
      <address>
        <city>Frankston</city>
        <state>Victoria</state>
        <zip>3199</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Border Medical Oncology</name>
      <address>
        <city>Wodonga</city>
        <state>Victoria</state>
        <zip>3690</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sir Charles Gairdner Hospital</name>
      <address>
        <city>Nedlands</city>
        <zip>6009</zip>
        <country>Australia</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinik Innsbruck</name>
      <address>
        <city>Innsbruck</city>
        <zip>6020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Salzburger Landkliniken St. Johanns-Spital</name>
      <address>
        <city>Salzburg</city>
        <zip>5020</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Medizinische Universität Wien</name>
      <address>
        <city>Vienna</city>
        <zip>1090</zip>
        <country>Austria</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centro de Oncologia Da Bahia</name>
      <address>
        <city>Salvador</city>
        <state>Bahia</state>
        <zip>41820-021</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Liga Paranaense de Combate Ao Cancer</name>
      <address>
        <city>Curitiba</city>
        <state>Paraná</state>
        <zip>81520-060</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Nacional de Cancer - INCA</name>
      <address>
        <city>Rio De Janerio</city>
        <state>Rio de Janeiro</state>
        <zip>20560-120</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Associacao Hospitalar Moinhos de Vento/ Hospital Moinhos de Vento</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90035-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Sao Lucas - PUCRS</name>
      <address>
        <city>Porto Alegre</city>
        <state>Rio Grande do Sul</state>
        <zip>90610-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Fundacao Pio XII - Hospital de Cancer de Barretos</name>
      <address>
        <city>Barretos</city>
        <state>São Paulo</state>
        <zip>14784-400</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Amaral Carvalho/ Hospital Amaral Carvalho Jaú</name>
      <address>
        <city>Jau/SP</city>
        <state>São Paulo</state>
        <zip>17210-080</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ONCOCLINIC Clinica de Oncologia LTDA</name>
      <address>
        <city>Fortaleza</city>
        <zip>60160-230</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital das Clinicas da Faculdade de Medicina da USP</name>
      <address>
        <city>Ribeirao Preto</city>
        <zip>14048-900</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Ribeiraopretano de Combate Ao Cancer</name>
      <address>
        <city>Ribeirao Preto</city>
        <zip>14015-130</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Bruno Born</name>
      <address>
        <city>Rio Grande do Sul</city>
        <zip>95900-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Base Da Faculdade de Medicina de</name>
      <address>
        <city>Sao Jose Do Rio Preto</city>
        <zip>15090-000</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Albert Einstein Sociedade Beneficente Israelita Brasileira</name>
      <address>
        <city>Sao Paulo</city>
        <zip>05651-901</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Brasileiro de Controle Do Câncer IBCC</name>
      <address>
        <city>São Paulo</city>
        <zip>03102-002</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sociedade Beneficente de Senhoras Hospital Sirio Libanês</name>
      <address>
        <city>São Paulo</city>
        <zip>01308-050</zip>
        <country>Brazil</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Ottawa General Hospital</name>
      <address>
        <city>Ottawa</city>
        <state>Ontario</state>
        <zip>K1H 8L6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CHUM - Notre Dame</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2L 4M1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital du Saint Scarement Sacrement Laboratory</name>
      <address>
        <city>Quebec City</city>
        <state>Quebec</state>
        <zip>G1S4L8</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>CSSS de Rimouski Neigette</name>
      <address>
        <city>Rimouski</city>
        <state>Quebec</state>
        <zip>G5L5T1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Alan Blair Cancer Centre at Pasqua Hosptial</name>
      <address>
        <city>Regina</city>
        <state>Saskatchewan</state>
        <zip>S4T1A5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre Jean Perrin</name>
      <address>
        <city>Clermont-Ferrand</city>
        <zip>63003</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sankt Gertrauden-Krankenhaus</name>
      <address>
        <city>Berlin</city>
        <zip>10713</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Agaplesion Markus Krankenhaus</name>
      <address>
        <city>Frankfurt</city>
        <zip>60431</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Praxis für interdisziplinäre Onkologie &amp; Hämatologie</name>
      <address>
        <city>Freiburg</city>
        <zip>79110</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitaetsklinikum Heidelberg</name>
      <address>
        <city>Heidelberg</city>
        <zip>69120</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Frauenärzte am Bahnhofsplatz</name>
      <address>
        <city>Hildesheim</city>
        <zip>31134</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Schwerpunktpraxis für Gynäkologische Onkologie</name>
      <address>
        <city>Köln</city>
        <zip>50679</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>LMU Klinikum der Universität</name>
      <address>
        <city>München</city>
        <zip>81377</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Krankenanstalt Mutterhaus der Borromäerinnen</name>
      <address>
        <city>Trier</city>
        <zip>54290</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universitatsklinikum Ulm</name>
      <address>
        <city>Ulm</city>
        <zip>89075</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IASO General</name>
      <address>
        <city>Athens</city>
        <zip>15562</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Athens Medical school - Regional General Hospital</name>
      <address>
        <city>Athens</city>
        <zip>11528</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Metropolitan Hospital</name>
      <address>
        <city>Faliro</city>
        <zip>18547</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Heraklion</name>
      <address>
        <city>Heraklion</city>
        <zip>71110</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University General Hospital of Patras</name>
      <address>
        <city>Rio Patras</city>
        <zip>26500</zip>
        <country>Greece</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Bologna - Policlinico S.Orsola-Malpighi</name>
      <address>
        <city>Bologna, Emilia-Romagna</city>
        <zip>40138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliero-Universitaria di Ferrara Arcispedale Sant' Anna</name>
      <address>
        <city>Ferrara</city>
        <zip>44124</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>IRCCS AziendaOspedaliera Universitaria San Martino</name>
      <address>
        <city>Genova</city>
        <zip>16132</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Presidio Ospedaliero della Misericordia</name>
      <address>
        <city>Grosseto</city>
        <zip>58100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Ospedali Riuniti Papardo-Piemonte</name>
      <address>
        <city>Messina</city>
        <zip>98158</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera San Gerardo</name>
      <address>
        <city>Monza</city>
        <zip>20900</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Universitaria Federico II</name>
      <address>
        <city>Napoli, Campania</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Per Lo Studio E La Cura Dei Tumori Fondazione Giovanni Pascale</name>
      <address>
        <city>Napoli, Campania</city>
        <zip>80131</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Oncologico Veneto</name>
      <address>
        <city>Padova</city>
        <zip>35128</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Arcispedale Santa Maria Nuova</name>
      <address>
        <city>Reggio Emilia</city>
        <zip>42100</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Sant' Andrea</name>
      <address>
        <city>Roma</city>
        <zip>00189</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Nazionale Tumori Regina Elena</name>
      <address>
        <city>Roma</city>
        <zip>144</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Policlinico Universitario A Gemelli</name>
      <address>
        <city>Roma</city>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Istituto Clinico Humanitas</name>
      <address>
        <city>Rozzano (MI)</city>
        <zip>20089</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Città della Salute e della Scienza di Torino</name>
      <address>
        <city>Torino, Piemonte</city>
        <zip>10126</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Azienda Ospedaliera Treviglio-Caravaggio</name>
      <address>
        <city>Treviglio</city>
        <zip>24047</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Espirito Santo</name>
      <address>
        <city>Evora</city>
        <zip>7000-811</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Da Luz</name>
      <address>
        <city>Lisboa</city>
        <zip>1500-650</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital de Santa Maria</name>
      <address>
        <city>Lisboa</city>
        <zip>1649-035</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Instituto Português de Oncologia do Porto, Francisco Gentil</name>
      <address>
        <city>Porto</city>
        <zip>4200-072</zip>
        <country>Portugal</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Clinic Barcelona Hospital Universitari</name>
      <address>
        <city>Barcelona</city>
        <zip>08036</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vall D`Hebron</name>
      <address>
        <city>Barcelona</city>
        <zip>8035</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Reina Sofía</name>
      <address>
        <city>Cordoba</city>
        <zip>14004</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital General &quot;Gregorio Maranon&quot;</name>
      <address>
        <city>Madrid</city>
        <zip>28007</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Onkologikoa - Kutxaren Institutu Onkologikoa</name>
      <address>
        <city>San Sebastian</city>
        <zip>20014</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Clinico Universitario de Santiago</name>
      <address>
        <city>Santiago de Compostela</city>
        <zip>15706</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Vírgen Macarena</name>
      <address>
        <city>Sevilla</city>
        <zip>41071</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hospital Universitario Miguel Servet</name>
      <address>
        <city>Zaragoza</city>
        <zip>50009</zip>
        <country>Spain</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Royal United Hospital</name>
      <address>
        <city>Bath</city>
        <zip>BA1 3NG</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sarah Cannon Research Institute UK</name>
      <address>
        <city>London</city>
        <zip>W1G 6AD</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Christie NHS Foundation Trust</name>
      <address>
        <city>Manchester</city>
        <zip>M20 4BX</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The East and North Hertfordshire NHS Trust</name>
      <address>
        <city>Middlesex</city>
        <zip>HA62RN</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Sheffield Teaching Hospitals NHS Foundation Trust</name>
      <address>
        <city>Sheffield South Yorkshire</city>
        <zip>S10 2SJ</zip>
        <country>United Kingdom</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
    <country>Australia</country>
    <country>Austria</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Greece</country>
    <country>Italy</country>
    <country>Portugal</country>
    <country>Spain</country>
    <country>United Kingdom</country>
  </location_countries>
  <verification_date>June 2015</verification_date>
  <lastchanged_date>June 12, 2015</lastchanged_date>
  <firstreceived_date>June 17, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Breast Cancer</keyword>
  <keyword>Cancer of the Breast</keyword>
  <keyword>Metastatic Breast Cancer</keyword>
  <keyword>Metastatic Triple Negative  Breast Cancer</keyword>
  <keyword>Triple Negative  Breast Cancer</keyword>
  <keyword>Triple Negative Metastatic  Breast Cancer</keyword>
  <keyword>Basal-like breast cancer</keyword>
  <keyword>Hormone receptor negative breast cancer</keyword>
  <keyword>Estrogen receptor negative breast cancer</keyword>
  <keyword>Progesterone negative receptor breast cancer</keyword>
  <keyword>HER2 Negative Breast Cancer</keyword>
  <keyword>Abraxane</keyword>
  <keyword>nab-Paclitaxel</keyword>
  <keyword>ABI-007</keyword>
  <keyword>gemcitabine</keyword>
  <keyword>Gemzar</keyword>
  <keyword>carboplatin</keyword>
  <keyword>Paraplatin</keyword>
  <keyword>Paraplatin AQ</keyword>
  <keyword>Phase 2</keyword>
  <keyword>Phase 3</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Breast Neoplasms</mesh_term>
    <mesh_term>Triple Negative Breast Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Paclitaxel</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
